Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis.

A clinical trial by Leventogiannis et al. suggests that ferritin and HLA-DR monocyte receptor expression can identify septic patients with macrophage-activation-like syndrome (MALS), or immunoparalysis, and that targeting IL-1ra treatment with this strategy may improve outcomes.